tetano
Editor, Senior Moderator
PLoS One
. 2024 Jul 16;19(7):e0304822.
doi: 10.1371/journal.pone.0304822. eCollection 2024. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
Christopher F Bell[SUP] 1 [/SUP], Daniel C Gibbons[SUP] 2 [/SUP], Myriam Drysdale[SUP] 2 [/SUP], Helen J Birch[SUP] 2 [/SUP], Emily J Lloyd[SUP] 2 [/SUP], Vishal Patel[SUP] 2 [/SUP], Corinne Carpenter[SUP] 3 [/SUP], Katherine Carlson[SUP] 3 [/SUP], Ediz S Calay[SUP] 3 [/SUP], Arjun Puranik[SUP] 3 [/SUP], Tyler E Wagner[SUP] 3 [/SUP], John C O'Horo[SUP] 4 [/SUP], Raymund R Razonable[SUP] 4 [/SUP]
Affiliations
Background: To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes.
Methods: This observational retrospective cohort study analyzed Mayo Clinic electronic health records. Non-hospitalized adult patients diagnosed with COVID-19 from May 26, 2021 and April 23, 2022 and at high risk of COVID-19 progression were eligible. The primary outcome was 29-day all-cause hospitalization and/or death. Outcomes were described for patients treated with sotrovimab, other mAbs, or antivirals, and eligible but untreated patients, and compared between sotrovimab-treated and propensity score (PS)-matched untreated cohorts.
Results: We included 35,485 patients (sotrovimab, 1369; other mAbs, 6488; antivirals, 133; high-risk untreated, 27,495). A low proportion of patients treated with sotrovimab (n = 33/1369, 2.4%), other mAbs (n = 147/6488, 2.3%), or antivirals (n = 2/133, 1.5%) experienced all-cause hospitalization or death. Among high-risk untreated patients, the percentage of all-cause hospitalization or death was 3.3% (n = 910/27,495). In the PS-matched analysis, 2.5% (n = 21/854) of sotrovimab-treated patients experienced all-cause hospitalization and/or death versus 2.8% (n = 48/1708) of untreated patients (difference, -0.4%; p = 0.66). Significantly fewer sotrovimab-treated patients required intensive care unit admission (0.5% vs 1.8%; difference, -1.3%; p = 0.002) or respiratory support (3.5% vs 8.7%; difference, -5.2%; p < 0.001).
Conclusions: There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.
. 2024 Jul 16;19(7):e0304822.
doi: 10.1371/journal.pone.0304822. eCollection 2024. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
Christopher F Bell[SUP] 1 [/SUP], Daniel C Gibbons[SUP] 2 [/SUP], Myriam Drysdale[SUP] 2 [/SUP], Helen J Birch[SUP] 2 [/SUP], Emily J Lloyd[SUP] 2 [/SUP], Vishal Patel[SUP] 2 [/SUP], Corinne Carpenter[SUP] 3 [/SUP], Katherine Carlson[SUP] 3 [/SUP], Ediz S Calay[SUP] 3 [/SUP], Arjun Puranik[SUP] 3 [/SUP], Tyler E Wagner[SUP] 3 [/SUP], John C O'Horo[SUP] 4 [/SUP], Raymund R Razonable[SUP] 4 [/SUP]
Affiliations
- PMID: 39012863
- PMCID: PMC11251586
- DOI: 10.1371/journal.pone.0304822
Background: To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes.
Methods: This observational retrospective cohort study analyzed Mayo Clinic electronic health records. Non-hospitalized adult patients diagnosed with COVID-19 from May 26, 2021 and April 23, 2022 and at high risk of COVID-19 progression were eligible. The primary outcome was 29-day all-cause hospitalization and/or death. Outcomes were described for patients treated with sotrovimab, other mAbs, or antivirals, and eligible but untreated patients, and compared between sotrovimab-treated and propensity score (PS)-matched untreated cohorts.
Results: We included 35,485 patients (sotrovimab, 1369; other mAbs, 6488; antivirals, 133; high-risk untreated, 27,495). A low proportion of patients treated with sotrovimab (n = 33/1369, 2.4%), other mAbs (n = 147/6488, 2.3%), or antivirals (n = 2/133, 1.5%) experienced all-cause hospitalization or death. Among high-risk untreated patients, the percentage of all-cause hospitalization or death was 3.3% (n = 910/27,495). In the PS-matched analysis, 2.5% (n = 21/854) of sotrovimab-treated patients experienced all-cause hospitalization and/or death versus 2.8% (n = 48/1708) of untreated patients (difference, -0.4%; p = 0.66). Significantly fewer sotrovimab-treated patients required intensive care unit admission (0.5% vs 1.8%; difference, -1.3%; p = 0.002) or respiratory support (3.5% vs 8.7%; difference, -5.2%; p < 0.001).
Conclusions: There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.